GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » Gross Profit

Clal Biotechnology Industries (XTAE:CBI) Gross Profit : ₪0.03 Mil (TTM As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries Gross Profit?

Clal Biotechnology Industries's gross profit for the six months ended in Jun. 2024 was ₪0.00 Mil. Clal Biotechnology Industries's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was ₪0.03 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Clal Biotechnology Industries's gross profit for the six months ended in Jun. 2024 was ₪0.00 Mil. Clal Biotechnology Industries's Revenue for the six months ended in Jun. 2024 was ₪0.00 Mil. Therefore, Clal Biotechnology Industries's Gross Margin % for the quarter that ended in Jun. 2024 was N/A%.

Clal Biotechnology Industries had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of Clal Biotechnology Industries was 4785.71%. The lowest was -2114.16%. And the median was -6.25%.


Clal Biotechnology Industries Gross Profit Historical Data

The historical data trend for Clal Biotechnology Industries's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries Gross Profit Chart

Clal Biotechnology Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.39 6.22 10.72 0.37 0.10

Clal Biotechnology Industries Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.29 0.07 0.03 -

Competitive Comparison of Clal Biotechnology Industries's Gross Profit

For the Biotechnology subindustry, Clal Biotechnology Industries's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clal Biotechnology Industries's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's Gross Profit distribution charts can be found below:

* The bar in red indicates where Clal Biotechnology Industries's Gross Profit falls into.


;
;

Clal Biotechnology Industries Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Clal Biotechnology Industries's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.104 - 0
=0.10

Clal Biotechnology Industries's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪0.03 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Clal Biotechnology Industries's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Clal Biotechnology Industries  (XTAE:CBI) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Clal Biotechnology Industries had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage


Clal Biotechnology Industries Gross Profit Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Clal Biotechnology Industries Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries Headlines

From GuruFocus

Van Den Berg Almost Sells Out 4 Stakes in 1st Quarter

By David Goodloe David Goodloe 04-20-2016

CB&I Announces Novolen Technology Award in China

By PRNewswire PRNewswire 04-03-2018

McDermott Announces Ethylene Furnace Award in Indonesia

By PRNewswire PRNewswire 01-24-2019

Chairman, CEO, CFO Purchase Shares in McDermott

By PRNewswire PRNewswire 11-07-2018

Van Den Berg Reduces Position in 5-Star Company

By Kyle Ferguson Kyle Ferguson 01-25-2016

Should We Devote Attention to Market Factors?

By Grahamites Grahamites 08-25-2015

McDermott Awarded Paraxylene (pX) Technology Contract in China

By PRNewswire PRNewswire 06-13-2019